Guo Chen

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

The pseudouridine epitranscriptomic landscape of advanced prostate cancer therapeutic resistance identifies TIMM17A as a key player.

The pseudouridine epitranscriptomic landscape of advanced prostate cancer therapeutic resistance identifies TIMM17A as a key player.

Journal: Translational oncology

Published: May 25, 2026

GG-NER's role in androgen receptor signaling inhibitor response for advanced prostate cancer.

GG-NER's role in androgen receptor signaling inhibitor response for advanced prostate cancer.

Journal: Cell communication and signaling : CCS

Published: September 05, 2024

Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.

Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.

Journal: Cancer letters

Published: August 28, 2023

Retraction Note: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Retraction Note: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Journal: Molecular cancer

Published: March 21, 2023

Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies.

Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies.

Journal: Discover oncology

Published: January 16, 2023

Expression status and prognostic value of autophagy-related lncRNAs in prostate cancer.

Expression status and prognostic value of autophagy-related lncRNAs in prostate cancer.

Journal: Cell cycle (Georgetown, Tex.)

Published: April 13, 2022

Suppression of ANT2 by miR-137 Inhibits Prostate Tumorigenesis.

Suppression of ANT2 by miR-137 Inhibits Prostate Tumorigenesis.

Journal: Frontiers in genetics

Published: April 08, 2021

Long Noncoding RNA SNHG12 Promotes Prostate Tumor Occurrence and Progression via AKT Regulation.

Long Noncoding RNA SNHG12 Promotes Prostate Tumor Occurrence and Progression via AKT Regulation.

Journal: BioMed research international

Published: September 18, 2020

An Eight-CircRNA Assessment Model for Predicting Biochemical Recurrence in Prostate Cancer.

An Eight-CircRNA Assessment Model for Predicting Biochemical Recurrence in Prostate Cancer.

Journal: Frontiers in cell and developmental biology

Published: August 27, 2020

Aberrant Expression of Citrate Synthase is Linked to Disease Progression and Clinical Outcome in Prostate Cancer.

Aberrant Expression of Citrate Synthase is Linked to Disease Progression and Clinical Outcome in Prostate Cancer.

Journal: Cancer management and research

Published: April 01, 2020

ARNT-dependent CCR8 reprogrammed LDH isoform expression correlates with poor clinical outcomes of prostate cancer.

ARNT-dependent CCR8 reprogrammed LDH isoform expression correlates with poor clinical outcomes of prostate cancer.

Journal: Molecular carcinogenesis

Published: August 21, 2019

Correction to: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Correction to: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Journal: Molecular cancer

Published: August 08, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026